摘要
目的:探讨葛根素对难治性心力衰竭患者血中氧化/抗氧化指标的调节作用。方法:选取健康成人34例,检测静脉血全血超氧 化物歧化酶(SOD)、全血谷胱甘肽过氧化物酶(GSH-Px)和过氧化氢酶(CAT)的活性及血浆脂质过氧化物(LPO)和丙二醛(MDA)的 浓度,然后与难治性心力衰竭组治疗前的此5项指标进行比较;选择76例难治性心力衰竭患者,随机分成两组,试验前均监测静脉血 全血 SOD、GSH-Px 和 CAT 的活性及血浆 LPO 和 MDA 的浓度并评价心功能,然后试验组在给予常规治疗的同时合并给予葛根素 注射液300 mg/d,稀释后静脉滴注,疗程2周;对照组只给予常规治疗,2周后,复测上述指标,比较各组治疗前后的变化。结果:1) 难 治性心力衰竭患者全血 SOD、全血 GSH-Px 和 CAT 的活性比健康对照组低,而血浆 LPO 及 MDA 的浓度比健康对照组高,均 P<0. 01;2) 葛根素组试验前后比较,全血 SOD、全血 GSH-Px 和 CAT 活性明显增高,且血浆 LPO 和全血 MDA 浓度明显降低,均P<0. 05;而对照组则无显著变化,P>0. 05;3) 葛根素组心力衰竭纠正的有效率显著高于对照组,P>0. 05。结论:难治性心力衰竭患者机 体的抗氧化防御能力降低,葛根素可通过提高机体的抗氧化能力,消除氧自由基和脂质过氧化物,起到纠正心力衰竭的作用。
Objective:To Explore the action of puerarin on oxidant/antioxidant system of refractory heart failure. Methods: 34 health adults were choiced as health control group, to assay and to compare their quantity of LPO , MDA and activity of SOD, GSH - Px and CAT of venous blood with refractory heart failure before treated with puerarin. 76 refractory heart failure patients were randomly assigned into two groups, the quantity of LPO, MDA and activity of SOD, GSH - Px, CAT of venous blood and the cardiac function were detected in all patients before the trial , in addition to the routine treatment, the puerarin group patients were given puerarin infusion intravenouly (300mg/d)for 2 weeks , but the control group patients were only given routine treatment. 2 weeks later , the above markers were measured again and the changes were compared. Results: The activity of SOD, GSH - Px and CAT of refractory heart failure patients group were lower than those in health adult group, but the quantity of LPO, MIDA were higher than those in health adult group( all P〈0. 05 ). 2 weeks later, the quantity of LPO and MDA in puerarin group were decreased significantly (P〈0.05), the activity of SOD, GSH - Px and CAT in puerarin group were increased significantly ( all P〈0. 05 ) , but there were no change in control group (P〉0. 05 ). Heart failure redressing rate of puerarin group were higher than that of control group ( all P〈0. 05 ). Conclusion: Puerarin can improve the antioxidation ability in refractory heart failure patients and it can ameliorate the cardiac function.
出处
《中国临床医学》
北大核心
2005年第5期927-929,共3页
Chinese Journal of Clinical Medicine